Sava Infond’s Regeneron Pharmaceuticals REGN Stock Holding History

Sava Infond’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$493K	Sell	650 -200	-24%	-$151K	0.03%	147
2026 Q2	$530K	Sell	850 -820	-49%	-$558K	0.04%	138
2026 Q1	$1.29M	Buy	1,670 +520	+45%	+$398K	0.18%	96
2025 Q4	$888K	Buy	1,150 +260	+29%	+$177K	0.12%	105
2025 Q3	$500K	Buy	890 +150	+20%	+$84.8K	0.07%	124
2025 Q2	$388K	Sell	740 -60	-8%	-$33.5K	0.06%	132
2025 Q1	$507K	Buy	800 +110	+16%	+$75.7K	0.1%	119
2024 Q4	$492K	Buy	+690	New	+$579K	0.09%	118

Other funds holding REGN

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Sava Infond's REGN Position: Q3 2026 in Review

Sava Infond reduced its Regeneron Pharmaceuticals (REGN) stake by 24% in Q3 2026, selling an estimated $151K and leaving 650 shares worth $493K. The position accounts for 0.03% of the portfolio, ranked #147.

Sava Infond first reported a position in REGN in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.29M in Q1 2026. 786 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

Sava Infond held 650 shares of Regeneron Pharmaceuticals worth $493K as of Q3 2026.
Sava Infond sold 200 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $151K.
Regeneron Pharmaceuticals made up 0.03% of Sava Infond's portfolio in Q3 2026, its #147 holding.
Sava Infond first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
Sava Infond's Regeneron Pharmaceuticals position peaked at $1.29M in Q1 2026.
786 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Sava Infond's 13F filing for Q3 2026, filed 28 Oct 2026.